Cargando…

The Battlefield of Chemotherapy in Pediatric Cancers

SIMPLE SUMMARY: The survival rate for pediatric cancers has improved significantly over the last decades. Conventional chemotherapies play a vital role in pediatric cancer treatment, especially in low- and middle-income countries, and the roster of chemo drugs for use in children has expanded. Howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Bo, Letao, Wang, Youyou, Li, Yidong, Wurpel, John N. D., Huang, Zoufang, Chen, Zhe-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093214/
https://www.ncbi.nlm.nih.gov/pubmed/37046624
http://dx.doi.org/10.3390/cancers15071963
_version_ 1785023531623383040
author Bo, Letao
Wang, Youyou
Li, Yidong
Wurpel, John N. D.
Huang, Zoufang
Chen, Zhe-Sheng
author_facet Bo, Letao
Wang, Youyou
Li, Yidong
Wurpel, John N. D.
Huang, Zoufang
Chen, Zhe-Sheng
author_sort Bo, Letao
collection PubMed
description SIMPLE SUMMARY: The survival rate for pediatric cancers has improved significantly over the last decades. Conventional chemotherapies play a vital role in pediatric cancer treatment, especially in low- and middle-income countries, and the roster of chemo drugs for use in children has expanded. However, patients suffer from chemotherapy as a result of its countless side effects. Furthermore, multidrug resistance (MDR) continues to be an insurmountable obstacle that limits survival for a considerable number of patients. In this review, we discuss severe side effects in pediatric chemotherapies such as doxorubicin-induced cardiotoxicity (DIC) and vincristine-induced peripheral neuropathy (VIPN). Here, MDR mechanisms in chemotherapy are elucidated with the aim of improving survival, while also reducing the intensity and toxicity of chemotherapy. Furthermore, we focus on various drug transporters in common types of pediatric tumors, which could provide different therapeutic strategies. ABSTRACT: The survival rate for pediatric cancers has remarkably improved in recent years. Conventional chemotherapy plays a crucial role in treating pediatric cancers, especially in low- and middle-income countries where access to advanced treatments may be limited. The Food and Drug Administration (FDA) approved chemotherapy drugs that can be used in children have expanded, but patients still face numerous side effects from the treatment. In addition, multidrug resistance (MDR) continues to pose a major challenge in improving the survival rates for a significant number of patients. This review focuses on the severe side effects of pediatric chemotherapy, including doxorubicin-induced cardiotoxicity (DIC) and vincristine-induced peripheral neuropathy (VIPN). We also delve into the mechanisms of MDR in chemotherapy to the improve survival and reduce the toxicity of treatment. Additionally, the review focuses on various drug transporters found in common types of pediatric tumors, which could offer different therapeutic options.
format Online
Article
Text
id pubmed-10093214
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100932142023-04-13 The Battlefield of Chemotherapy in Pediatric Cancers Bo, Letao Wang, Youyou Li, Yidong Wurpel, John N. D. Huang, Zoufang Chen, Zhe-Sheng Cancers (Basel) Review SIMPLE SUMMARY: The survival rate for pediatric cancers has improved significantly over the last decades. Conventional chemotherapies play a vital role in pediatric cancer treatment, especially in low- and middle-income countries, and the roster of chemo drugs for use in children has expanded. However, patients suffer from chemotherapy as a result of its countless side effects. Furthermore, multidrug resistance (MDR) continues to be an insurmountable obstacle that limits survival for a considerable number of patients. In this review, we discuss severe side effects in pediatric chemotherapies such as doxorubicin-induced cardiotoxicity (DIC) and vincristine-induced peripheral neuropathy (VIPN). Here, MDR mechanisms in chemotherapy are elucidated with the aim of improving survival, while also reducing the intensity and toxicity of chemotherapy. Furthermore, we focus on various drug transporters in common types of pediatric tumors, which could provide different therapeutic strategies. ABSTRACT: The survival rate for pediatric cancers has remarkably improved in recent years. Conventional chemotherapy plays a crucial role in treating pediatric cancers, especially in low- and middle-income countries where access to advanced treatments may be limited. The Food and Drug Administration (FDA) approved chemotherapy drugs that can be used in children have expanded, but patients still face numerous side effects from the treatment. In addition, multidrug resistance (MDR) continues to pose a major challenge in improving the survival rates for a significant number of patients. This review focuses on the severe side effects of pediatric chemotherapy, including doxorubicin-induced cardiotoxicity (DIC) and vincristine-induced peripheral neuropathy (VIPN). We also delve into the mechanisms of MDR in chemotherapy to the improve survival and reduce the toxicity of treatment. Additionally, the review focuses on various drug transporters found in common types of pediatric tumors, which could offer different therapeutic options. MDPI 2023-03-24 /pmc/articles/PMC10093214/ /pubmed/37046624 http://dx.doi.org/10.3390/cancers15071963 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bo, Letao
Wang, Youyou
Li, Yidong
Wurpel, John N. D.
Huang, Zoufang
Chen, Zhe-Sheng
The Battlefield of Chemotherapy in Pediatric Cancers
title The Battlefield of Chemotherapy in Pediatric Cancers
title_full The Battlefield of Chemotherapy in Pediatric Cancers
title_fullStr The Battlefield of Chemotherapy in Pediatric Cancers
title_full_unstemmed The Battlefield of Chemotherapy in Pediatric Cancers
title_short The Battlefield of Chemotherapy in Pediatric Cancers
title_sort battlefield of chemotherapy in pediatric cancers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093214/
https://www.ncbi.nlm.nih.gov/pubmed/37046624
http://dx.doi.org/10.3390/cancers15071963
work_keys_str_mv AT boletao thebattlefieldofchemotherapyinpediatriccancers
AT wangyouyou thebattlefieldofchemotherapyinpediatriccancers
AT liyidong thebattlefieldofchemotherapyinpediatriccancers
AT wurpeljohnnd thebattlefieldofchemotherapyinpediatriccancers
AT huangzoufang thebattlefieldofchemotherapyinpediatriccancers
AT chenzhesheng thebattlefieldofchemotherapyinpediatriccancers
AT boletao battlefieldofchemotherapyinpediatriccancers
AT wangyouyou battlefieldofchemotherapyinpediatriccancers
AT liyidong battlefieldofchemotherapyinpediatriccancers
AT wurpeljohnnd battlefieldofchemotherapyinpediatriccancers
AT huangzoufang battlefieldofchemotherapyinpediatriccancers
AT chenzhesheng battlefieldofchemotherapyinpediatriccancers